SCHEMBL6929327

SCHEMBL6929327

CC(C)(C)C(=O)N1CCC(Nc2cc(Nc3cccc(Cl)c3)nc3c(/C=C4\NC(=O)NC4=O)cnn23)CC1

nearest known ligand 0.42

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 9/20 0.42
CSNK2B P67870 8/20 0.42
CSNK2A1 P68400 1/20 0.42
EGFR P00533 2/20 0.39
TYRO3 Q06418 1/20 0.38
MERTK Q12866 1/20 0.38
BTK Q06187 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2029930 1.00 CSNK2A2 (0.42) CSNK2A2CSNK2BCSNK2A1EGFRTYRO3
SCHEMBL2029932 1.00 CSNK2A2 (0.42) CSNK2A2CSNK2BCSNK2A1EGFRTYRO3
SCHEMBL2030986 0.91 CSNK2B (0.41) CSNK2A2CSNK2BCSNK2A1EGFRBTK
SCHEMBL2031069 0.91 CSNK2B (0.40) CSNK2A2CSNK2BCSNK2A1EGFR
SCHEMBL2031070 0.91 CSNK2B (0.40) CSNK2A2CSNK2BCSNK2A1EGFR
SCHEMBL2030987 0.91 CSNK2B (0.41) CSNK2A2CSNK2BCSNK2A1EGFRBTK
SCHEMBL17641224 0.91 CSNK2A2 (0.42) CSNK2A2CSNK2BCSNK2A1EGFRBTK
SCHEMBL2030917 0.91 CSNK2A2 (0.42) CSNK2A2CSNK2BCSNK2A1EGFRBTK
SCHEMBL6929843 0.91 CSNK2A2 (0.42) CSNK2A2CSNK2BCSNK2A1EGFRBTK
SCHEMBL2030915 0.91 CSNK2A2 (0.42) CSNK2A2CSNK2BCSNK2A1EGFRBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2509602-B9 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS SENHWA BIOSCIENCES INC (TW) 2017-11-01 EP disclosed
EP-2509602-B1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS SENHWA BIOSCIENCES INC (TW) 2017-01-25 EP disclosed
US-9303033-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2016-04-05 US disclosed
US-9303033-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2016-04-05 US disclosed
US-8575177-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2013-11-05 US disclosed
US-8575177-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2013-11-05 US disclosed
WO-2012170827-A2 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2012-12-13 WO disclosed
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-23 US disclosed
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-23 US disclosed
WO-2011068667-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CDK2, CKS2, CSNK2A1 CSNK2A2 5/4885CSNK2B 13/4885CSNK2A1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.